Publications by authors named "James Lapolla"

8 Publications

  • Page 1 of 1

Woringer-Kolopp Disease of the Foot: A Case Report.

J Am Podiatr Med Assoc 2020 Nov;110(6)

Woringer-Kolopp disease is a rare variant of mycosis fungoides, a type of cutaneous T-cell lymphoma. Described is a case of a small annular plaque on the foot diagnosed histologically as Woringer-Kolopp disease and treated successfully with topical and intralesional steroids. In addition, a brief review of the literature and treatment options is provided.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.7547/18-029DOI Listing
November 2020

Traumatic neuroma of the posterior tibial nerve due to previous surgery presenting as a massive tumor in the midfoot: A case report.

Foot (Edinb) 2019 Jun 18;39:68-71. Epub 2019 Feb 18.

Attending Physician, Trumbull Memorial Regional Hospital, 1350 E Market St, Warren, OH 44483 USA.

A case report of traumatic neuroma, a benign non-neoplastic tumor of the posterior tibial nerve is presented. The soft tissue mass in the midfoot region was likely a sequela of previous nerve decompression surgery that the patient underwent five years previously in the same region and on the same nerve. Physical examination and history taking, along with an MRI, were important steps in reaching a definitive diagnosis of traumatic neuroma based on the findings of an interventional radiologist and histopathological evaluation of the biopsy by a pathologist. The lesion was subsequently surgically removed utilizing a multidisciplinary management approach. The patient recovered uneventfully and no symptom recurrence was noted at the 30-month follow-up. The tumor was the largest reported in the literature at the time. This case was also unique in that the patient was relieved of pronation and regained tactile sensation in the midfoot.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.foot.2019.02.008DOI Listing
June 2019

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Gynecol Oncol 2013 Jul 25;130(1):19-24. Epub 2013 Apr 25.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Objectives: The efficacy and safety of bevacizumab and docetaxel were evaluated in women who developed recurrent epithelial ovarian, fallopian, or peritoneal cancer within 12 months of platinum-based therapy.

Methods: Patients received docetaxel (40 mg/m(2)) on days 1 and 8 and bevacizumab (15 mg/kg) on day 1 of a 21-daycycle. Primary endpoint was 6-month progression-free survival (PFS).

Results: Forty-one patients were evaluable for PFS and 38 for best response; 46% had platinum-free intervals (PFI) of <6 months and 54% between 6 and 12 months. The 6-month PFS was 43.9% (95% confidence interval (CI(95%))=28.6-58.2%). Median PFS (months) was 5.2 (CI(95%)=4.4-7.2) for all patients, 6.2 (CI(95%)=4.1-7.4) for patients with PFI <6 months, and 5.1 (CI(95%)=3.0-7.2) for those with PFI ≥ 6 months. Twenty-two patients showed overall response (CR+PR) (57.9%; CI(95%)=40.8-73.7%), and 32 showed clinical benefit (CR+PR+SD) (84.2%; CI(95%)=68.8-94.0%). For those with complete or partial responses, median duration of response was 4.8 months (0.7-14.5). Median overall survival was 12.4 months (CI(95%)=10.0-21.9). The most common grade 3/4 adverse events (AEs) were neutropenia (14.6% of patients), followed by leukopenia, fatigue, metabolic, and gastrointestinal, with 66% showing any grade 3/4 toxicity. Most common AEs of any grade were gastrointestinal (93%), fatigue (73%), and pain (73%). Four (10%) patients developed hypertension, 1 a gastrointestinal perforation, and another a colovesicular fistula.

Conclusions: Bevacizumab and docetaxel administered in patients with recurrent ovarian cancer is an active regimen without new unanticipated toxicities. This combination should be an option for further study or clinical use in recurrent ovarian cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.04.049DOI Listing
July 2013

Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

PLoS One 2012 17;7(10):e46846. Epub 2012 Oct 17.

Frantz Biomarkers, LLC, Mentor, Ohio, USA.

Background: More than two-thirds of women who undergo surgery for suspected ovarian neoplasm do not have cancer. Our previous results suggest phospholipids as potential biomarkers of ovarian cancer. In this study, we measured the serum levels of multiple phospholipids among women undergoing surgery for suspected ovarian cancer to identify biomarkers that better predict whether an ovarian mass is malignant.

Methodology/principal Findings: We obtained serum samples preoperatively from women with suspected ovarian cancer enrolled through a prospective, population-based rapid ascertainment system. Samples were analyzed from all women in whom a diagnosis of epithelial ovarian cancer (EOC) was confirmed and from benign disease cases randomly selected from the remaining (non-EOC) samples. We measured biologically relevant phospholipids using liquid chromatography/electrospray ionization mass spectrometry. We applied a powerful statistical and machine learning approach, Hybrid huberized support vector machine (HH-SVM) to prioritize phospholipids to enter the biomarker models, and used cross-validation to obtain conservative estimates of classification error rates.

Results: The HH-SVM model using the measurements of specific combinations of phospholipids supplements clinical CA125 measurement and improves diagnostic accuracy. Specifically, the measurement of phospholipids improved sensitivity (identification of cases with preoperative CA125 levels below 35) among two types of cases in which CA125 performance is historically poor - early stage cases and those of mucinous histology. Measurement of phospholipids improved the identification of early stage cases from 65% (based on CA125) to 82%, and mucinous cases from 44% to 88%.

Conclusions/significance: Levels of specific serum phospholipids differ between women with ovarian cancer and those with benign conditions. If validated by independent studies in the future, these biomarkers may serve as an adjunct at the time of clinical presentation, to distinguish between women with ovarian cancer and those with benign conditions with shared symptoms and features.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046846PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474784PMC
April 2013

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.

Authors:
Paul D P Pharoah Rachel T Palmieri Susan J Ramus Simon A Gayther Irene L Andrulis Hoda Anton-Culver Natalia Antonenkova Antonis C Antoniou David Goldgar Mary S Beattie Matthias W Beckmann Michael J Birrer Natalia Bogdanova Kelly L Bolton Wendy Brewster Angela Brooks-Wilson Robert Brown Ralf Butzow Trinidad Caldes Maria Adelaide Caligo Ian Campbell Jenny Chang-Claude Y Ann Chen Linda S Cook Fergus J Couch Daniel W Cramer Julie M Cunningham Evelyn Despierre Jennifer A Doherty Thilo Dörk Matthias Dürst Diana M Eccles Arif B Ekici Douglas Easton Peter A Fasching Anna de Fazio David A Fenstermacher James M Flanagan Brooke L Fridley Eitan Friedman Bo Gao Olga Sinilnikova Aleksandra Gentry-Maharaj Andrew K Godwin Ellen L Goode Marc T Goodman Jenny Gross Thomas V O Hansen Paul Harnett Matti Rookus Tuomas Heikkinen Rebecca Hein Claus Høgdall Estrid Høgdall Edwin S Iversen Anna Jakubowska Sharon E Johnatty Beth Y Karlan Noah D Kauff Stanley B Kaye Georgia Chenevix-Trench Linda E Kelemen Lambertus A Kiemeney Susanne Krüger Kjaer Diether Lambrechts James P Lapolla Conxi Lázaro Nhu D Le Arto Leminen Karin Leunen Douglas A Levine Yi Lu Lene Lundvall Stuart Macgregor Tamara Marees Leon F Massuger John R McLaughlin Usha Menon Marco Montagna Kirsten B Moysich Steven A Narod Katherine L Nathanson Lotte Nedergaard Roberta B Ness Heli Nevanlinna Stefan Nickels Ana Osorio Jim Paul Celeste Leigh Pearce Catherine M Phelan Malcolm C Pike Paolo Radice Mary Anne Rossing Joellen M Schildkraut Thomas A Sellers Christian F Singer Honglin Song Daniel O Stram Rebecca Sutphen Annika Lindblom Kathryn L Terry Ya-Yu Tsai Anne M van Altena Ignace Vergote Robert A Vierkant Allison F Vitonis Christine Walsh Shan Wang-Gohrke Barbara Wappenschmidt Anna H Wu Argyrios Ziogas Andrew Berchuck Harvey A Risch

Clin Cancer Res 2011 Jun 8;17(11):3742-50. Epub 2011 Mar 8.

Department of Oncology, University of Cambridge, Cambridge, United Kingdom.

Purpose: An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. However, only one published article, analyzing fewer than 1,000 subjects in total, has examined this association.

Experimental Design: Risk association was evaluated in 8,669 cases of invasive EOC and 10,012 controls from 19 studies participating in the Ovarian Cancer Association Consortium, and in 683 cases and 2,044 controls carrying BRCA1 mutations from studies in the Consortium of Investigators of Modifiers of BRCA1/2. Prognosis association was also examined in a subset of five studies with progression-free survival (PFS) data and 18 studies with all-cause mortality data.

Results: No evidence of association was observed between genotype and risk of unselected EOC (OR = 1.02, 95% CI: 0.95-1.10), serous EOC (OR = 1.08, 95% CI: 0.98-1.18), familial EOC (OR = 1.09, 95% CI: 0.78-1.54), or among women carrying deleterious mutations in BRCA1 (OR = 1.09, 95% CI: 0.88-1.36). There was little evidence for association with survival time among unselected cases (HR = 1.10, 95% CI: 0.99-1.22), among serous cases (HR = 1.12, 95% CI = 0.99-1.28), or with PFS in 540 cases treated with carboplatin and paclitaxel (HR = 1.18, 95% CI: 0.93-1.52).

Conclusions: These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer. Use of this SNP for ovarian cancer clinical risk prediction, therefore, seems unwarranted.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107901PMC
June 2011

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Cancer 2005 Dec;104(12):2807-16

Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33617, USA.

Background: It is believed that BRCA1 and BRCA2 germline mutations account for the majority of hereditary ovarian carcinomas; however, to the authors' knowledge, there are scant data on the prevalence and spectrum of mutations, genotype/phenotype correlations, tumor histology, and family history characteristics. To address this gap, the authors conducted a population-based study of 232 incident epithelial ovarian carcinomas in the Tampa Bay area.

Methods: Genetic testing for the BRCA1 and BRCA2 genes was performed through full sequencing and BRCA1 rearrangement testing.

Results: Of 209 women with invasive ovarian carcinoma, 32 women (15.3%) had mutations in BRCA1 or BRCA2, including 20 BRCA1 mutations and 12 BRCA2 mutations. Of the BRCA2 mutations, 58% were outside the "ovarian cancer cluster region" (OCCR). Variants of uncertain significance were detected in 8.2% of women with invasive ovarian carcinoma. No mutations were identified in women with borderline or invasive mucinous tumors. Among the BRCA mutation-positive women, 63% had serous tumors. A family history of breast and/or ovarian carcinoma was reported in 65%, 75%, and 43.5% of relatives of BRCA1 carriers, BRCA2 carriers, and non-BRCA1/BRCA2 carriers, respectively.

Conclusions: The data from this study suggested that 1) previous studies may have underestimated the frequency of BRCA1 and BRCA2 mutations in ovarian carcinomas, especially outside the OCCR; 2) it may be reasonable to offer genetic counseling to any woman with an invasive, nonmucinous epithelial ovarian tumor; and 3) among patients with invasive ovarian carcinoma, family history is not sufficiently accurate to predict mutation status.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21536DOI Listing
December 2005

Lysophospholipids are potential biomarkers of ovarian cancer.

Cancer Epidemiol Biomarkers Prev 2004 Jul;13(7):1185-91

Department of Interdisciplinary Oncology, College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, 33612, USA.

Objective: To determine whether lysophosphatidic acid (LPA) and other lysophospholipids (LPL) are useful markers for diagnosis and/or prognosis of ovarian cancer in a controlled setting.

Method: Plasma samples were collected from ovarian cancer patients and healthy control women in Hillsborough and Pinellas counties, Florida, and processed at the University of South Florida H. Lee Moffitt Cancer Center and Research Institute (Moffitt). Case patients with epithelial ovarian cancer (n = 117) and healthy control subjects (n = 27) participated in the study. Blinded LPL analysis, including 23 individual LPL species, was performed at the Cleveland Clinic Foundation using an electrospray ionization mass spectrometry-based method. LPL levels were transmitted to Moffitt, where clinical data were reviewed and statistical analyses were performed.

Results: There were statistically significant differences between preoperative case samples (n = 45) and control samples (n = 27) in the mean levels of total LPA, total lysophosphatidylinositol (LPI), sphingosine-1-phosphate (S1P), and individual LPA species as well as the combination of several LPL species. The combination of 16:0-LPA and 20:4-LPA yielded the best discrimination between preoperative case samples and control samples, with 93.1% correct classification, 91.1% sensitivity, and 96.3% specificity. In 22 cases with both preoperative and postoperative samples, the postoperative levels of several LPL, including S1P, total LPA, and lysophosphatidylcholine (LPC) levels and some individual species of LPA and LPC, were significantly different from preoperative levels.

Conclusion: LPA, LPI, LPC, and S1P appear useful as diagnostic and prognostic biomarkers of ovarian cancer.
View Article and Find Full Text PDF

Download full-text PDF

Source
July 2004